Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 05, 2026 07:00 ET | Source: NeurAxis, Inc.

NeurAxis to Host First Quarter 2026 Results and Business Update Call on Tuesday, May 12, 2026

CARMEL, Ind., May 05, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing...
April 29, 2026 08:19 ET | Source: Biomerica, Inc.

Biomerica’s inFoods® IBS Data Accepted for Presentation at Digestive Disease Week 2026

IRVINE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global biomedical technology company focused on innovative diagnostic-guided therapies, today announced that an...
April 22, 2026 07:00 ET | Source: NeurAxis, Inc.

NeurAxis Expands Payer Coverage with Four New Medical Policies

CARMEL, Ind., April 22, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for...
April 16, 2026 08:19 ET | Source: Biomerica, Inc.

Biomerica Announces Medicare Administrative Contractor Confirmation of Individual Claim Review for inFoods® IBS, Opening a Scalable Medicare Commercialization Pathway

The Medicare Administrative Contractor (MAC) responsible for processing inFoods® IBS claims has confirmed to Biomerica’s certified laboratory partner that the test will be reviewed on an individual,...
April 14, 2026 08:19 ET | Source: Biomerica, Inc.

Biomerica Launches inFoods® IBS in Canada Through Partnerships with Phoenix Airmid Biomedical and CanAlt Health Labs

— Represents Biomerica’s First Commercial Entry into the Canadian Market for its Precision, Diagnostic-Guided Therapy — Canada Has One of the Highest IBS Prevalence Rates in the World — an Estimated...
April 10, 2026 07:00 ET | Source: NeurAxis, Inc.

NeurAxis, Inc. Announces Preferred Stock Dividend

CARMEL, Ind., April 10, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for...
April 02, 2026 07:10 ET | Source: Cylinder Health

Cylinder Health launches Stool Scan to innovate and standardize one of GI care’s most subjective signals

Cylinder Health launches Stool Scan, the first clinically validated stool imaging AI built into a virtual GI care platform. Available to all members now.
March 19, 2026 07:05 ET | Source: NeurAxis, Inc.

NeurAxis Reports Strong Fourth Quarter and Full Year 2025 Financial Results

CARMEL, Ind., March 19, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for...
March 12, 2026 09:00 ET | Source: NeurAxis, Inc.

NeurAxis to Host Fourth Quarter and Full Year 2025 Results and Business Update Call on Thursday, March 19, 2026

CARMEL, Ind., March 12, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies...
February 26, 2026 08:19 ET | Source: Biomerica, Inc.

Biomerica Reports Real-World Data: Nearly 60% of IBS Patients Achieved Clinically Meaningful Pain Reduction and 68% Achieved Bloating Reduction with the inFoods® IBS Therapy

Key Highlights Responder Analysis: 59.4% of patients achieved ≥30% reduction in abdominal pain; 68.1% achieved ≥30% reduction in bloating—using the FDA-recognized responder endpoint consistent...